|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
|
27960087 |
2016 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NQO1 genotypes of 390 men did not indicate predisposition to CaP, yet loss of NQO1 in CaP suggested potential progression-opposing tumour suppressor role.
|
26987799 |
2016 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we present a treatment strategy that makes BER inhibition tumor-selective and NQO1-dependent for therapy of most solid neoplasms, particularly for pancreatic cancer.
|
26602448 |
2015 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The positive rate of NQO1 was related with clinical stage and lymph node metastasis, and the strongly positive rate of NQO1 protein was significantly correlated with tumor size, poor differentiation, advanced clinical stage and lymph node metastasis in NSCLC.
|
25880877 |
2015 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NQO1 protein expression was assessed using immunohistochemical (IHC) staining in 160 patients with serous ovarian carcinoma, 62 patients with ovarian borderline tumors and 53 patients with benign ovarian tumors.
|
25885439 |
2015 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The rate of strong positive NQO1 protein expression was correlated with large tumor size (P=0.019), late pathologic stage (P=0.001) and the presence of lymph node metastasis (P=0.001).
|
25231218 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
|
25341038 |
2014 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Additionally, the NQO1 expression rate was positively correlated with tumor size, serosal invasion, tumor stage, and both disease-free survival and 5-year survival rates.
|
24384455 |
2014 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The FANCD2-associated survival effect was most pronounced in hormone receptor positive, HER2-negative tumors, and in tumors with above-median NQO1 expression.
|
23897704 |
2013 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed.
|
22532167 |
2012 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NQO1 protein expression was associated with estrogen receptor (ER) expression (P = 0.011), whereas 34.5% of NFκB-nuclear/activated tumors were ER negative (P = 0.001).
|
21706157 |
2012 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The present study did not find any significant association of NQO1 609C>T and NQO2 -3423G>A polymorphisms with susceptibility to EC or its clinical phenotypes (histopathology, tumor location or lymph node metastasis) or interactions with lifestyle risk factors (tobacco usage, smoking, alcohol habit and occupational exposures).
|
22770696 |
2012 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Secondary objectives were assessment of toxicity, pharmacokinetic determination of RH1 and pharmacodynamic assessment of drug effect through measurement of DNA cross linking in peripheral blood mononuclear cells (PBMCs) and tumour, DTD activity in tumour and NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphism status.
|
21378203 |
2011 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NQO1 deficiency promotes estrogen-dependent tumor formation, and shikonin inhibits estrogen-dependent tumor growth in an NQO1-dependent manner in MCF-7 xenografts.
|
20623181 |
2010 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our data showed that (1) the frequency of C609T NQO1 was significantly increased in TNM stage III HCC patients; (2) no significant association was found between p53 expression and C609T polymorphism of NQO1 gene; and (3) a tumor/non-tumor (T/N) ratio > 1.27 of NQO1 expression revealed by real-time qPCR analyses was positively correlated with poorer survival in patients with tumors >5 cm, suggesting that an increase of NQO1 expression may be an indicator of advanced tumor progression.
|
19688691 |
2009 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, we did not find preferential targeting of the active NQO1 allele in tumors with LOH at 16q.
|
18416817 |
2008 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We show elevated NAD(P)H:quinone oxidoreductase-1 (NQO1) levels in tumors from NSCLC patients. beta-Lapachone, an effective chemotherapeutic and radiosensitizing agent, selectively killed NSCLC cells that expressed high levels of NQO1.
|
17609380 |
2007 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H:quinone oxidoreductase 1 (NQO1) is elevated in several human tumors.
|
16532285 |
2006 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H:quinone oxidoreductase 1 (NQO1) regulates the stability of the tumor suppressor WT p53.
|
15809436 |
2005 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a key enzyme involved in defence against reactive forms of oxygen and inhibition of neoplasia.
|
15476858 |
2004 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High levels of NQO1 expression were observed throughout xenograft tumors established from the NQ16 cell line.
|
15131056 |
2004 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In summary, RH1 can be effective in killing cells containing high levels of DTD and may be useful in treating tumors expressing this enzyme.
|
15090746 |
2004 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A broad spectrum of NQO1 protein expression existed in tumours genotyped as NQO1*1 and NQO1*1/*2 although tumours with NQO1*1 typically expressed higher NQO1 protein.
|
15375541 |
2004 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Xenografts established from the clonal lines exhibited significant tumor control following MMC treatment (treated/control [T/C] 17% and 51% for DTD and P450R xenografts, respectively) that was not seen in wild-type tumors (T/C 102%).
|
14555709 |
2003 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These data indicate that the NQO1 609C>T polymorphism results in significantly reduced tumor NQO1 activity and reduced survival in subsets of patients receiving intraperitoneal hyperthermic mitomycin C therapy.
|
11773862 |
2002 |